Replies to post #33545 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Donja: yes, and that is the language that makes the other part vague:

"As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities."

When read in conjunction with "we read the data and decided not to pursue the expansion phase" it is unclear whether they decided not to continue because the data alone didn't warrant it, or whether they meant "because the data was not overwhelming, and due to the cost-benefit we are prioritizing other programs over HER2."

[Big Barnie]

Cantor Fitzgerald addressed the HER2 issue and said "Instead, ADXS plans to direct resources to cervical and prostate cancer, ADXS-NEO and ADXS-HOT. We like the idea of focusing the portfolio
and ADXS has chosen areas where the co. has both critical mass and novel technology, in our view"